SFN prolonged progression free survival (PFS) of advanced or metastatic HER2 negative BC patients (SOLTI-0701) [21] and advanced HER2 negative patients with disease progression during or after Bevacizumab treatment (NCT00493636 trial) [22]. Here, ERBB2 is linked to breast cancer.